Non-traditional settings for influenza vaccination of adults: Costs and cost effectiveness

PharmacoEconomics

Volumn 26, Issue 2, 2008, Pages 163-178

  Prosser, Lisa A ^a   O'Brien, Megan A ^a   Molinari, Noelle Angelique M ^b   Hohman, Katherine H ^a   Nichol, Kristin L ^c   Messonnier, Mark L ^b   Lieu, Tracy A ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cost effectiveness; Influenza virus infections, prevention; Influenza virus vaccine, therapeutic use

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DRUG COST; DRUG EFFECT; GROUPS BY AGE; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MASS IMMUNIZATION; MORTALITY; PHARMACIST; PHARMACY; POPULATION RESEARCH; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 38349002638     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826020-00006     Document Type: Article

References (47)

1. US Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2010 [online]. Available from URL: http://www.healthypeople.gov [Accessed 2007 Nov 26]
2. Thompson WW, Shay D, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289 (2): 179-86
3. Thompson WW, Shay D, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292 (11): 1333-40
4. Smith NM, Shay D, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Morb Mortal Wkly Rep 2006; 55 (29): 800]. MMWR Recomm Rep 2006; 55 (RR-10): 1-42
5. Allos BM, Bresee JS. Influenza vaccine session introduction. Advisory Committee on Immunization Practices; 2006 Oct 25; Atlanta (GA)
6. Singleton JA, Poel AJ, Lu P-J, et al. Where adults reported receiving influenza vaccination in the United States. Am J Infect Control 2005; 33: 563-70
7. Coleman MS, Fontanesi J, Meltzer MI, et al. Estimating medical practice expenses from administering adult influenza vaccinations. Vaccine 2005; 23: 915-23
8. Hebert PL, Frick KD, Kane RL, et al. The causes of racial and ethnic differences in influenza vaccination rates among elderly Medicare beneficiaries. HSR 2005; 40 (2): 517-37
9. US Department of Labor, Bureau of Labor Statistics. National compensation survey: occupational wages in the United States, July 2003 [online]. Available from URL: http://www.bls.gov/ncs/ocs/sp/ncbl0658.pdf [Accessed 2007 Nov 21]
10. Cornelius L, Beauregard K, Cohen J. Usual sources of medical care and their characteristics. National Medical Expenditure Survey Research Findings 11. AHCPR Publication No. 90-00042. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, 1991
11. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169: 68-76
12. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284 (13): 1655-63
13. Keitel WA, Cate TR, Couch RB, et al. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997; 15 (10): 1114-22
14. Gorse GJ, O'Connor TZ, Young SL, et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003; 21 (17-18): 2133-44
15. Govaert TME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. JAMA 1994; 272 (21): 1661-5
16. Nichol KL, Mendelman P, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282 (2): 137-44
17. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333 (14): 889-93
18. Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998; 158 (16): 1769-76
19. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002; 35: 370-7
20. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5 (5): 659-71
21. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348 (14): 1322-32
22. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123 (7): 518-27
23. Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on excess deaths occurring during periods of high circulation of influenza: cohort study in elderly people. BMJ 2004; 329: 660-3
24. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med 1996; 156 (14): 1546-50
25. Halperin SA, Smith B, Mabrouk T, et al. Safety and immunocompensation genicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20 (7-8): 1240-7
26. Scheifele DW, Bjornson G, Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ 1990; 142 (2): 127-30
27. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18 (9-10): 899-906
28. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial [published erratum appears in JAMA 1991 Jun 5; 265 (21): 2810]. JAMA 1990; 264 (9): 1139-41
29. Retailliau HF, Curtis AC, Storr G, et al. Illness after influenza vaccination reported through a nationwide surveillance system, 1976-1977. Am J Epidemiol 1980; 111: 270-8
30. Institute of Medicine of the National Academies: Immunization Safety Review Committee BoHPaDP. Immunization safety review: influenza vaccines and neurological complications. Washington, DC: The National Academies Press, 2004
31. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086-96
32. Grosse SD. Prevention effectiveness: a guide to decision analysis and economic evaluation [appendix I: productivity loss tables]. 2nd ed. New York: Oxford University Press, 2003: 245-57
33. Nichol KL. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine 1999; 17: S67-73
34. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21: 1769-75
35. Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165 (3): 265-72
36. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertainty 2003; 27 (1): 5-76
37. Weinstein MC, O'Brien B, Hornberger M, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9-17
38. Hunink MGM, Glasziou PP, Siegel JE, et al. Decision making in health and medicine: integrating evidence and values. New York: Cambridge University Press, 2001
39. US Department of Health and Human Services. Influenza and pneumococcal vaccination coverage among persons aged > 65 years: United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2006; 55 (39): 1065-8
40. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess (Rockv) 2003; 7 (15): 1-178
41. Demicheli V, Rivetti D, Deeks J, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3): CD001269
42. Reuer J, Brown C, Eulger GL, et al. Factors associated with where people go for their influenza vaccination. National Immunization Program Conference; 2004 May 12; Atlanta (GA)
43. Prosser LA, Bridges CB, Uyeki TM, et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes 2005; 3 (18): 1-16
44. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137: 225-31
45. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21: 2207-17
46. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35 (2): 337-44
47. Bearden DT, Holt T. Statewide impact of pharmacist-delivered adult influenza vaccinations. Am J Prev Med 2005; 29 (5): 450-2